1 – 20 of 63
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Beyond Average : a-Particle Distribution and Dose Heterogeneity in Bone Metastatic Prostate Cancer
(
- Contribution to journal › Article
- 2023
-
Mark
Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response
(
- Contribution to journal › Article
- 2022
-
Mark
Prostate cancer polygenic risk score and prediction of lethal prostate cancer
(
- Contribution to journal › Article
- 2021
-
Mark
Improved 223Ra Therapy with Combination Epithelial Sodium Channel Blockade
(
- Contribution to journal › Article
-
Mark
PSA-Targeted Alpha-, Beta-, and Positron-emitting immunotheranostics in murine prostate cancer models and nonhuman primates
(
- Contribution to journal › Article
- 2020
-
Mark
Preclinical Single Photon Emission Computed Tomography of Alpha Particle-Emitting Radium-223
(
- Contribution to journal › Article
-
Mark
Genome-wide association study identifies novel single nucleotide polymorphisms having age-specific effect on prostate-specific antigen levels
(
- Contribution to journal › Article
-
Mark
Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy
2020) In Proceedings of the National Academy of Sciences of the United States of America 117(26). p.15172-15181(
- Contribution to journal › Article
- 2019
-
Mark
Harnessing androgen receptor pathway activation for targeted alpha particle radioimmunotherapy of breast cancer
(
- Contribution to journal › Article
-
Mark
Kallikrein markers performance in pretreatment blood to predict early prostate cancer recurrence and metastasis after radical prostatectomy among very high-risk men
2019) In Prostate(
- Contribution to journal › Article
-
Mark
Preclinical efficacy of hK2 targeted [177Lu]hu11B6 for prostate cancer theranostics
(
- Contribution to journal › Article
- 2018
-
Mark
Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men
(
- Contribution to journal › Article
-
Mark
Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival
(
- Contribution to journal › Article
-
Mark
Long-term prediction of prostate cancer diagnosis and death using PSA and obesity related anthropometrics at early middle age : Data from the malmö preventive project
(
- Contribution to journal › Article
-
Mark
Association Between Lead Time and Prostate Cancer Grade : Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening
(
- Contribution to journal › Article
-
Mark
Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer
(
- Contribution to journal › Article
-
Mark
Androgen deprivation therapy potentiates the efficacy of vascular targeted photodynamic therapy of prostate cancer xenografts
(
- Contribution to journal › Article
- 2017
-
Mark
Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study
(
- Contribution to journal › Article
-
Mark
In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME)
(
- Contribution to journal › Article
- 2016
-
Mark
Vitamin D, PTH, and calcium and tumor aggressiveness in prostate cancer: a prospective nested case-control study.
(
- Contribution to journal › Article